Leo Wealth LLC Decreases Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Leo Wealth LLC cut its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 35.3% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 7,571 shares of the biopharmaceutical company's stock after selling 4,134 shares during the period. Leo Wealth LLC's holdings in Gilead Sciences were worth $848,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of GILD. Norges Bank bought a new stake in shares of Gilead Sciences during the 4th quarter valued at $1,789,254,000. FMR LLC lifted its holdings in shares of Gilead Sciences by 21.6% during the 4th quarter. FMR LLC now owns 40,319,432 shares of the biopharmaceutical company's stock worth $3,724,306,000 after acquiring an additional 7,157,113 shares during the last quarter. GAMMA Investing LLC lifted its holdings in shares of Gilead Sciences by 13,891.1% during the 1st quarter. GAMMA Investing LLC now owns 2,550,298 shares of the biopharmaceutical company's stock worth $285,761,000 after acquiring an additional 2,532,070 shares during the last quarter. Northern Trust Corp lifted its stake in Gilead Sciences by 19.7% in the fourth quarter. Northern Trust Corp now owns 14,915,095 shares of the biopharmaceutical company's stock worth $1,377,707,000 after purchasing an additional 2,458,954 shares during the last quarter. Finally, Royal Bank of Canada lifted its stake in Gilead Sciences by 30.1% in the fourth quarter. Royal Bank of Canada now owns 8,678,751 shares of the biopharmaceutical company's stock worth $801,655,000 after purchasing an additional 2,005,863 shares during the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Gilead Sciences Price Performance

GILD stock traded down $0.77 during trading on Thursday, reaching $109.08. The company's stock had a trading volume of 1,698,779 shares, compared to its average volume of 7,658,983. The company has a market capitalization of $135.69 billion, a P/E ratio of 22.95, a price-to-earnings-growth ratio of 0.71 and a beta of 0.29. The company's fifty day moving average is $108.37 and its 200-day moving average is $104.94. The company has a quick ratio of 1.23, a current ratio of 1.37 and a debt-to-equity ratio of 1.16. Gilead Sciences, Inc. has a 1 year low of $70.78 and a 1 year high of $119.96.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 EPS for the quarter, topping analysts' consensus estimates of $1.77 by $0.04. The business had revenue of $6.67 billion for the quarter, compared to analyst estimates of $6.77 billion. Gilead Sciences had a net margin of 20.76% and a return on equity of 51.93%. The company's quarterly revenue was down .3% compared to the same quarter last year. During the same period last year, the company posted ($1.32) earnings per share. On average, research analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, June 27th. Stockholders of record on Friday, June 13th were paid a dividend of $0.79 per share. The ex-dividend date was Friday, June 13th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.90%. Gilead Sciences's dividend payout ratio is currently 66.53%.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on GILD shares. Cantor Fitzgerald started coverage on shares of Gilead Sciences in a report on Tuesday, April 22nd. They issued an "overweight" rating and a $125.00 price objective on the stock. JPMorgan Chase & Co. raised their price objective on shares of Gilead Sciences from $120.00 to $130.00 and gave the company an "overweight" rating in a research report on Thursday, March 27th. Morgan Stanley lifted their price target on shares of Gilead Sciences from $130.00 to $135.00 and gave the company an "overweight" rating in a report on Friday, April 25th. Needham & Company LLC reissued a "hold" rating on shares of Gilead Sciences in a research note on Wednesday, May 21st. Finally, Oppenheimer dropped their price target on shares of Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating for the company in a research note on Friday, April 25th. Nine investment analysts have rated the stock with a hold rating, fourteen have given a buy rating and three have given a strong buy rating to the company's stock. According to MarketBeat.com, Gilead Sciences has a consensus rating of "Moderate Buy" and an average target price of $111.38.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the business's stock in a transaction dated Tuesday, July 15th. The shares were sold at an average price of $111.03, for a total value of $277,575.00. Following the transaction, the chief financial officer directly owned 162,610 shares in the company, valued at $18,054,588.30. The trade was a 1.51% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Johanna Mercier sold 3,000 shares of the stock in a transaction that occurred on Tuesday, July 15th. The stock was sold at an average price of $111.03, for a total transaction of $333,090.00. Following the sale, the insider owned 117,168 shares in the company, valued at approximately $13,009,163.04. This trade represents a 2.50% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 72,000 shares of company stock worth $7,844,775 in the last 90 days. 0.27% of the stock is currently owned by insiders.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.